| Document |
Document Title |
|
WO/2011/003342A1 |
Disclosed is a kind of carboxylate compound, shown as general formula I, wherein the definition of each group is seen in the description. The compound has excellent herbicidal activity, and can effectively control barnyard millet, crabgr...
|
|
WO/2011/005322A2 |
The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for det...
|
|
WO/2010/150946A1 |
Disclosed is a method for the preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester, comprising the asymmetric reduction of arylketone and the carbamation of alcohol.
|
|
WO/2010/144959A1 |
The present invention relates to analogues of anti-fibrotic agents having the formula (I) with the substituents as described within the specification. The present invention also relates to methods for their preparation.
|
|
WO/2010/147666A1 |
Compounds are disclosed that have formula (I'): wherein A, W, Cy1, Cy2, L1, L2, R1 and R2 are as defined herein. The compounds and pharmaceutical compositions thereof are useful as probes and imaging agents for identifying hypoxic tumors...
|
|
WO/2010/136037A1 |
The invention relates to novel calcium-sensing receptor (CaSR) modulating substituted cyclopentylene compounds represented in formula I and derivatives thereof, to said compounds for use as a medicament, to said compounds for use in ther...
|
|
WO/2010/133909A2 |
The present invention is a process for preparing sterically hindered 5-substituted tetrazole, which comprises of reacting a nitrile with an organotin halide and an azide in presence of a phase transfer catalyst, in an organic solvent and...
|
|
WO/2010/132992A1 |
3D protein modeling and virtual screening of commercially-available compounds were performed to identify new inhibitors of the herpesvirus DNA polymerase, a key enzyme in the viral replication cycle. Two compounds (Nos 2 and 9) were part...
|
|
WO/2010/127440A1 |
The present invention relates to substituted aromatic compounds of Formula (I) and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds in the prevention and/or treatment of various diseases...
|
|
WO/2010/123017A1 |
Disclosed are: a compound represented by formula (I) or a pharmaceutically acceptable salt thereof; and use of the compound or the pharmaceutically acceptable salt thereof for medical purposes. In the formula, RA2 and RA3 independently r...
|
|
WO/2010/122968A1 |
Disclosed is a compound useful as an anti-obesity agent. Studies have been made on compounds which have a DGAT1 inhibitory activity and are therefore promising active ingredients for pharmaceutical compositions for treating obesity, type...
|
|
WO/2010/056205A9 |
The present invention provides Gd-chelates modified so as to comprise an amino acid unit attached to the chelate via a linker group suitably selected from C2-4alkylene and C3-5alkynylene, and the use of such chelates as an intravascular ...
|
|
WO/2010/114308A1 |
The present invention relates to novel amino acid derivatives containing heterocyclic chelating residues thereof; radioactive or nonradioactive metal complexes thereof; methods for preparation thereof; and apyrogenic and sterile preparat...
|
|
WO2010109851A1 |
Disclosed is a novel lubricant composition which is useful as a material for a lubrication layer in a magnetic recording medium. The lubricant composition contains at least one compound represented by formula (1). In the formula, X repre...
|
|
WO/2010/108125A2 |
Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.
|
|
WO/2010/103783A1 |
A process for the preparation of 1-alkyl-5-benzoyl-1H-tetrazole derivatives, which comprises: step (1) of reacting a keto-amide derivative represented by formula (I) [wherein A is a halogen atom or the like; n is an integer of 0 to 5; an...
|
|
WO/2010/076033A9 |
The present invention provides novel compounds that inhibit cell proliferation and cell division and that inhibit the activation of Hypoxia Inducible Factor (HIF)-mediated transcription and signaling under hypoxic conditions. In one aspe...
|
|
WO/2010/091169A2 |
Processes for preparing valsartan and essentially amorphous valsartan are described.
|
|
WO/2010/086615A1 |
The invention provides a compound of formula (I): wherein: R1 is an optionally substituted 2-(1-azathiaxanthone); each -R2 is independently of the formula -CH2-C(=O)-R4, wherein R4 is an amino acid or a salt thereof, attached to the rema...
|
|
WO/2010/085583A1 |
Embodiments of the present subject matter provide a compound and material that may be used as a lead-free primary explosive. An embodiment of the present subject matter provides the compound copper(I) nitrotetrazolate. Certain embodiment...
|
|
WO/2010/075869A1 |
The present invention provides novel compounds that inhibit cell proliferation and cell division and that inhibit the activation of Hypoxia Inducible Factor (HIF)- mediated transcription and signaling under hypoxic conditions. In one asp...
|
|
WO/2010/074089A1 |
Provided are novel low-molecular compounds which exhibit calcium receptor antagonist activity, and which are highly safe and orally administrable, namely, compounds having general formula (I) or pharmacologically acceptable salts thereof...
|
|
WO/2010/071559A1 |
The present invention provides a process for the manufacture of the compound 3-{4-methyl-5-[(1R)-1-(2-(3-methylphenyl-2H-tetrazol-5-yl)-e
thoxy]-4H-[1,2,4]triazol-3-yl}-pyridine of formula 14 wherein a) the compound 3-(5-methanesulfonyl-...
|
|
WO/2010/067913A1 |
The present invention relates to a method of removing triphenylmethane protection group. The method for preparing biphenyl benzoic acid derivatives of the present invention is economically advantageous and very excellent in the aspect of...
|
|
WO/2010/063724A1 |
Nitrate derivatives of cilostazol are described. They have superior properties and clinical advantages compared to cilostazol in the treatment of vascular and metabolic diseases.
|
|
WO/2010/065432A1 |
A compound having the structure wherein R is an angiotensin receptor antagonist active group, and Y is Y is selected from the group consisting of R1 is selected from the group consisting of -O-C 1-6 alkyl, -O-aryl, -O-heteroaryl, -O-C 3-...
|
|
WO/2010/056527A2 |
The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the co...
|
|
WO/2010/055207A1 |
This invention relates to a group of chelating agents, novel chelates, biomolecules labeled with these chelates or chelating agents as well as solid supports conjugated with these chelates, chelating agents and labeled biomolecules. The ...
|
|
WO/2010/055005A1 |
The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts and esters thereof, wherein X, Q, and R1-R6 are defined in the detailed description and claims. In addition, the present invention relates...
|
|
WO/2010/043000A1 |
The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions cau...
|
|
WO/2010/041748A1 |
Disclosed is a prophylactic or therapeutic agent for diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, heart failure, cardiomyopathy, myocardial ischemia, cer...
|
|
WO/2010/025197A1 |
This invention relates to a new synthesis, intermediates and precursors leading to a mixture of the compounds 11 and 12 as shown below. It also relates to the resolution of the stereoisomeric mixture to provide in substantial stereochemi...
|
|
WO/2010/022565A1 |
Tetrazole derivatives, poly(dimethylsiloxane) (PDMS) surface-functionalized with the same and methods for making said PDMS. The surface-functionalized PDMS is applicable in the general fields of microfluidics, bioMEMS (bio-microelectrome...
|
|
WO/2010/021351A1 |
Disclosed is a therapeutic agent for hyperparathyroidism, renal osteodystrophy, hypercalcemia and the like, which has a CaSR activating (agonistic) activity. Specifically disclosed is a compound represented by general formula (1) [wherei...
|
|
WO/2010/022249A2 |
The invention provides macrocyclic compounds and methods for their synthesis and use. In particular, the invention provides macrocyclic compounds that modulate the activity of tumor necrosis factor alpha and/or are useful in the treatmen...
|
|
WO/2010/016549A1 |
A tricyclic compound having a PPARĪ³-agonistic activity which is represented by general formula (I) [wherein Z represents a single bond or the like; Y represents a hydrogen atom, an optionally substituted lower alkyl or the like; X repre...
|
|
WO/2010/012442A2 |
The present invention relates to a novel benzenedicarboxamide derivative and the use thereof as an insecticide having the formula (I) wherein the chemical groups W1 to W9, and R1 to R3 are as defined herein.
|
|
WO/2010/009879A2 |
The present invention is directed to novel processes for the preparation of paricalcitol to novel intermediates used in these processes, and to processes for preparation of the novel intermediates.
|
|
WO/2010/009508A1 |
A compound of Formula (A) wherein Z is an aryl, substituted aryl, heteroaryl, or substituted heteroaryl, wherein the heteroaryl or substituted heteroaryl connected to a 2,4-dinito-6-(trifluoromethyl)phenyl ring via a carbon-carbon bond.
|
|
WO/2010/006755A2 |
The invention pertains to a compound for detecting cell death. According to the invention, the compound comprises a cyclic polyamine unit for the complexation of a bi- or trivalent metal ion. The compound of the invention may contain a r...
|
|
WO/2010/003084A2 |
PDE4 inhibition is achieved by novel compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formula I: wherein R1, R2, R3, and R4 are as defined herein.
|
|
WO/2009/158561A1 |
A composition including at least one peroxide-generating electrocatalyst, preferably a guinone, at least one peroxide-activation catalyst, preferably an iron complex of a tetraamido macrocyclic ligand, and carbon. The compositions may- b...
|
|
WO/2009/150248A1 |
The present invention relates to a compound of general formula (I) : and also to the pharmaceutically acceptable salts thereof, to the isomers or isomer mixtures thereof in all proportions, in particular to an enantiomer mixture, and esp...
|
|
WO/2009/148291A2 |
There are disclosed racemic or enantiomerically enriched 3- or 4-substituted piperidine compounds represented by the following structural formula (I) or any of their isomers, or pharmaceutically acceptable salts thereof. Also disclosed a...
|
|
WO/2009/148290A2 |
Racemic or enantiomerically enriched 3-substituted propanamine compounds represented by the following structural formula (I) or a pharmaceutically acceptable salt thereof are disclosed. Pharmaceutical compositions containing the subject ...
|
|
WO/2009/145219A1 |
Disclosed is a means for treating Alzheimer's disease, which utilizes a secretase inhibitor and is highly safe. Specifically disclosed is a compound represented by general formula (I) [wherein A represents a phenyl group or the like; R1...
|
|
WO/2009/127715A1 |
The present invention relates to novel compounds of formula (I) and (II), compositions comprising compounds of formula (II) and their use as contrast agents in magnetic resonance (MR) imaging (MRI) and MR spectroscopy (MRS).
|
|
WO/2009/125606A1 |
Provided is a compound represented by formula (I) having a PAI-1 inhibiting action. [In formula (I), R1 represents an optionally substituted C6-10 aryl group etc., T represents a single bond etc., m is 0 or 1, when m is 0 G represents -N...
|
|
WO/2009/124962A2 |
The invention relates to compounds of formula (I) wherein R1, R2, R4, Ra, Rb, Rc, Re, A*, W1, W2 and W3 are as defined in claim 1, for the treatment of CXCR3 related diseases.
|
|
WO/2009/124764A1 |
The invention relates to a compound composed of a metal ion, or metal, such as a radiopharmaceutical from a metal radio-nuclide, and a marker precursor, which is constructed of a bi-functional, macrocyclic chelator, a spacer, a linker, a...
|
